ClinicalTrials.gg
CompletedNCT06583486Updated Jun 29, 2026

A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

A Phase 3 interventional study of Rcombinant botulinum neurotoxin type A for injection (YY001) in Moderate to Severe Glabellar Lines, sponsored by Chongqing Claruvis Pharmaceutical Co., Ltd.. Completed at 16 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Chongqing Claruvis Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2024, registered Jul 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
488
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Multi-center, Open-label Study on the Efficacy and Safety of Multiple Treatments with Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines. The study has been designed to evaluate the long-term safety, tolerability, efficacy , maintain time and immunogenicity of multiple treatments with Recombinant Botulinum Toxin Type A for Injection (YY001) in the treatment of moderate to severe glabellar lines.

02

Conditions studied

  • Moderate to Severe Glabellar Lines

Keywords

  • YY001
  • Recombinant Botulinum Toxin Type A
  • Botulinum Toxin
  • Glabellar Lines
03

In context

Lead sponsor

Chongqing Claruvis Pharmaceutical Co., Ltd. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female 18 to 65 years (inclusive) at the time of signing the form.
  2. At screening or baseline, participants who complete all visits of the REFINE study without major protocol deviations and SAEs
  3. Agree to participate in the study and sign the informed consent form.
  4. At the discretion of the investigator, the participants can comply with the protocol requirements.
  5. Females and/or males of and their partners: those who should be using effective and have no plans for childbearing, egg donation (females), or sperm donation (males) from the signing of the informed consent form to 3 months after the last administration. female participants of childbearing potential must have had a negative blood pregnancy test (human chorionic gonadotropin) within 7 days prior to the first administration of study drug or a Urine pregnancy test examination must be negative 3 days prior to the first administration of study drug.

Note:

  1. Women of childbearing potential are those who have experienced menarche, have not undergone sterilization (hysterectomy or bilateral salpingo-oophorectomy or bilateral tubal ligation), and are not in a state of (defined as absence of menstrual bleeding for 12 months prior to screening, without any other medical reason).
  2. Effective contraceptives include: vasectomy, abstinence, intrauterine devices, hormones [oral, patch, ring, injections, implants], barrier methods [diaphragm, cervical cap, sponge, condom].

Exclusion criteria

Exclusion Criteria:

  1. Use of medications or treatments prohibited by the REFINE study protocol.
  2. Any condition that required permanent discontinuation of study treatment during the REFINE study.
  3. Use of nonsteroidal anti-inflammatory drugs including aspirin or anticoagulants within 1 week prior to baseline.
  4. Abnormal laboratory tests that, in the assessment of the investigator, are not appropriate for participation in this study: including, but not limited to: (ALT)/aspartate aminotransferase (AST) ≥ 2.5 times the (×ULN), creatinine ≥ 2 ×ULN, urea/urea nitrogen ≥ 2 ×ULN.
  5. Female who is pregnant or breast feeding.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
488 participants (actual)

Study arms

  • Experimental
    Treatment Group

    Five sites will be repeatedly injected with Rcombinant botulinum neurotoxin type A for injection (YY001) at 0.05 mL each, 2 sites in corrugator muscle of each side and 1 site in the procerus muscle, for a total dose of 20U.The study period is up to 64 weeks, divided into 5 treatment cycles.

    Biological: Rcombinant botulinum neurotoxin type A for injection (YY001)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of serious adverse events and drug-related adverse events during the study.

    Time frame: Up to 64 weeks

Secondary outcomes

  1. The proportion of participants who achieve a score of 0 or 1 on the investigator's assessment of GL severity.

    Glabellar lines at maximal frown are based on the 4 grade Facial Wrinkle Scale: 0 (none), 1 (mild), 2 (moderate) and 3 (severe).

    Time frame: At Weeks 1, 4, 12, 24 (if applicable), and 36 (if applicable) after each treatment.

  2. The proportion of participants who achieve a score of 0 or 1 on the participant's self-assessment and Independent Review Committee's assessment of GL severity photos at maximal frown taken on-site.

    Time frame: At Weeks 1(for participants), 4, 12, 24 (if applicable), and 36 (if applicable) after each treatment.

  3. The respond rate on the investigator's assessment of GL severity at maximal frown.

    The respond rate: The proportion of participants achieving a score of 0 or 1 and at least a two-grade improvement from the baseline, on the investigator's assessment and the participant's self-assessment concurrently of GL severity at maximal frown.

    Time frame: At Weeks 1, 4, 12, 24 (if applicable), and 36 (if applicable) after each treatment.

  4. The proportion of participants with a decrease of at least 1 grade from the baseline, on the investigator's assessment and the participant's self-assessment individually of GL severity at rest.

    The severity of glabellar lines at rest will be assessed according to the 4 grade scale: 0 (none), 1 (mild), 2 (moderate) and 3 (severe).

    Time frame: At Weeks 1, 4, 12, 24 (if applicable), and 36 (if applicable) after each treatment.

  5. Incidence of anti-drug antibodies and neutralizing antibodies during the study.

    Time frame: Up to 64 weeks

  6. The lasting time from a single injection to the participants' score of GL severity at maximal frown on the investigator's assessment return to the baseline.

    Time frame: Up to 64 weeks

07

Study locations

16 sites
  • Guangdong Second People's Hospital
    Guangzhou, Guangdong, China
  • Nanfang Hospital, Southern Medical University
    Guangzhou, Guangdong, China
  • The Third Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong, China
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The Second Affiliated Hospital Of Xi'an Jiaotong University
    Xian, Shanxi, China
  • West China School of Medicine/West China Hospital of Sichuan University
    Chengdu, Sichuan, China
  • Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine
    Hangzhou, Zhejiang, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang, China
  • Beijing Tsinghua Changgung Hospital
    Beijing, China
  • Peking Union Medical College Hospital , Chinese Academy of Medical Sciences
    Beijing, China
  • Peking University First Hospital
    Beijing, China
  • Peking University Third Hospital
    Beijing, China
  • Plastic Surgery Hospital, Chinese Academy of Medical Science
    Beijing, China
  • The First Affiliated Hospital of Chongqing Medical University
    Hongqing, China
  • Tianjin Medical University General Hospital
    Tianjin, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Aug 2025, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2024
First posted
Sep 4, 2024
StartActual
Mar 19, 2024
Primary completionActual
Aug 25, 2025
CompletionActual
Aug 25, 2025
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06583486
Lead sponsor
Chongqing Claruvis Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Sep 4, 2024
Start date
Mar 19, 2024
Primary completion
Aug 25, 2025
Completion
Aug 25, 2025
Last update
Jun 29, 2026

Study contacts

Yan Wu
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EP4 Receptor Antagonist YY001

Start the discussion